 "Glenmark Pharma plans to out-license molecule for pain management")
The Mumbai-based Glenmark Pharmaceuticals is planning to out-license its molecule for pain management. The molecule, GRC 17536, is expected to have a market potential worth $1 billion. According to a Business Standard report, Glenmark is in talks with a few multinational giants and a deal is likely in a couple of months.
The molecule has successfully completed phase-II trials on 138 patients in Europe and India.
In September 2014, Glenmark Pharmaceuticals had announced that its transient receptor potential ankyrin 1 (TRPA1) antagonist, GRC 17536, has shown positive data in a Phase 2a double blind, placebo controlled, multi-centre, proof of concept study conducted on 138 patients in Europe and India. The Glenmark TRPA1 program included indications in pain as well as respiratory.
The molecule has successfully completed phase-II trials on 138 patients in Europe and India.
In September 2014, Glenmark Pharmaceuticals had announced that its transient receptor potential ankyrin 1 (TRPA1) antagonist, GRC 17536, has shown positive data in a Phase 2a double blind, placebo controlled, multi-centre, proof of concept study conducted on 138 patients in Europe and India. The Glenmark TRPA1 program included indications in pain as well as respiratory.